Iben Lyskjær

1.1k citations
17 papers · 297 indexed · h-index 11
Topics
Cancer Genomics and Diagnostics (10 papers)Sarcoma Diagnosis and Treatment (5 papers)Renal cell carcinoma treatment (5 papers)

In The Last Decade

Iben Lyskjær

16 papers receiving 296 citations

Peers

Iben Lyskjær
Comparison fields: 5 of 53
  • Cancer Research 158
  • Molecular Biology 146
  • Pulmonary and Respiratory Medicine 134
  • Oncology 81
  • Pathology and Forensic Medicine 49
Replace Érica Boldrini with:
Érica Boldrini Brazil
Lucia Tombolan Italy
Samantha Brownhill United Kingdom
Nobuhiko Nishijima Japan
Christoph R. Müller Norway
Aurélie Maran-Gonzalez France
Jiazheng Cao China
Guoguang Shao China
Iben Lyskjær relative to Érica Boldrini Brazil Érica Boldrini's profile →
Citations per field
00.5×1.5×2.4×
Érica Boldrini · 1×
Citations per year

Countries citing papers authored by Iben Lyskjær

Since Specialization
Citations

This map shows the geographic impact of Iben Lyskjær's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iben Lyskjær with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iben Lyskjær more than expected).

Fields of papers citing papers by Iben Lyskjær

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iben Lyskjær. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iben Lyskjær. The network helps show where Iben Lyskjær may publish in the future.

Co-authorship network of co-authors of Iben Lyskjær

This figure shows the co-authorship network connecting the top 25 collaborators of Iben Lyskjær. A scholar is included among the top collaborators of Iben Lyskjær based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iben Lyskjær. Iben Lyskjær is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
#WorkIndexed citations
1 2
2 1
3 0
4 5
5 18
6 5
7 13
8 14
9 2
10 21
11 10
12 35
13 17
14 20
15 32
16 32
17 70

About Iben Lyskjær

Iben Lyskjær is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 17 papers that have together received 297 indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (10 papers), Sarcoma Diagnosis and Treatment (5 papers) and Renal cell carcinoma treatment (5 papers). The work is most often cited by research in Cancer Research (158 citations), Pulmonary and Respiratory Medicine (134 citations) and Oncology (81 citations). Iben Lyskjær has collaborated with scholars based in Denmark, United Kingdom and Switzerland. Frequent co-authors include Mads H. Rasmussen, Claus L. Andersen, Adrienne M. Flanagan, Torben F. Ørntoft, Fernanda Amary, Hongtao Ye, Jakob Skou Pedersen, Niels Fristrup, Tine Plato Hansen and Per Pfeiffer. Their work appears in journals such as Nature Communications, Scientific Reports and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026